Kiora Pharmaceuticals (NASDAQ:KPRX) Stock Price Down 1.1% – Should You Sell?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) shares traded down 1.1% during trading on Tuesday . The stock traded as low as $3.42 and last traded at $3.45. 12,917 shares were traded during mid-day trading, a decline of 83% from the average session volume of 75,676 shares. The stock had previously closed at $3.49.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Kiora Pharmaceuticals in a report on Thursday, August 22nd.

Kiora Pharmaceuticals Trading Up 2.8 %

The company’s fifty day moving average price is $3.56 and its 200-day moving average price is $4.41.

Kiora Pharmaceuticals (NASDAQ:KPRX) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.42. The firm had revenue of $0.02 million for the quarter. As a group, sell-side analysts predict that Kiora Pharmaceuticals, Inc. will post 1.17 EPS for the current fiscal year.

Institutional Investors Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC purchased a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals makes up about 0.8% of Stonepine Capital Management LLC’s portfolio, making the stock its 16th largest holding. Stonepine Capital Management LLC owned approximately 6.86% of Kiora Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.